The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11 (link))-dien-28-oic acid (CDDO) along with chemically modified derivatives, CDDO-Me (methyl ester, also known as bardoxolone methyl, BARD) and CDDO-EA (ethyl amide) are non-cytotoxic, highly multifunctional and orally available drugs that have been studied as anti-inflammatory and anti-oxidation agents in vivo and in vitro (43 (link)–45 (link)). Because ethyl amide derivative of a synthetic triterpenoid, CDDO-EA, has been reported to have enhanced pharmacodynamic activity in mouse assays compared to CDDO-Me (46 (link)), CDDO-EA (400 mg/kg diet) (provided from Reata Pharmaceuticals, Irving Texas, and Dr. Michael Sporn, Dartmouth Medical School, NH, USA) was first dissolved in an oily vehicle and prepared into chow pellets (Lab Diet #5002) by Purina (Purina-Mills, Richmond, IN, USA) (47 (link)). Group of mice were continuously fed a CDDO-EA diet or Control diet (Lab Diet #5002) for 3 days prior to radiation exposure.